Dataset Information

An empirical Bayes approach to normalization and differential abundance testing for microbiome data.

ABSTRACT: BACKGROUND:Advances in DNA sequencing have offered researchers an unprecedented opportunity to better study the variety of species living in and on the human body. However, the analysis of microbiome data is complicated by several challenges. First, the sequencing depth may vary by orders of magnitude across samples. Second, species are rare and the data often contain many zeros. Third, the specimen is a fraction of the microbial ecosystem, and so the data are compositional carrying only relative information. Other characteristics of microbiome data include pronounced over-dispersion in taxon abundances, and the existence of a phylogenetic tree that relates all bacterial species. To address some of these challenges, microbiome analysis workflows often normalize the read counts prior to downstream analysis. However, there are limitations in the current literature on the normalization of microbiome data. RESULTS:Under the multinomial distribution for the read counts and a prior for the unknown proportions, we propose an empirical Bayes approach to microbiome data normalization. Using a tree-based extension of the Dirichlet prior, we further extend our method by incorporating the phylogenetic tree into the normalization process. We study the impact of normalization on differential abundance analysis. In the presence of tree structure, we propose a phylogeny-aware detection procedure. CONCLUSIONS:Extensive simulations and gut microbiome data applications are conducted to demonstrate the superior performance of our empirical Bayes method over other normalization methods, and over commonly-used methods for differential abundance testing. Original R scripts are available at GitHub (https://github.com/liudoubletian/eBay).

SUBMITTER: Liu T

PROVIDER: S-EPMC7268703 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:MotivationMicrobial communities have been proved to have close relationship with many diseases. The identification of differentially abundant microbial species is clinically meaningful for finding disease-related pathogenic or probiotic bacteria. However, certain characteristics of microbiome data have hurdled the accuracy and effectiveness of differential abundance analysis. The abundances or counts of microbiome species are usually on different scales and exhibit zero-inflation and over-dispersion. Normalization is a crucial step before the differential abundance test. However, existing normalization methods typically try to adjust counts on different scales to a common scale by constructing size factors with the assumption that count distributions across samples are equivalent up to a certain percentile. These methods often yield undesirable results when differentially abundant species are of low to medium abundance level. For differential abundance analysis, existing methods often use a single distribution to model the dispersion of species which lacks flexibility to catch a single species' distinctiveness. These methods tend to detect a lot of false positives and often lack of power when the effect size is small.ResultsWe develop a novel framework for differential abundance analysis on sparse high-dimensional marker gene microbiome data. Our methodology relies on a novel network-based normalization technique and a two-stage zero-inflated mixture count regression model (RioNorm2). Our normalization method aims to find a group of relatively invariant microbiome species across samples and conditions in order to construct the size factor. Another contribution of the paper is that our testing approach can take under-sampling and over-dispersion into consideration by separating microbiome species into two groups and model them separately. Through comprehensive simulation studies, the performance of our method is consistently powerful and robust across different settings with different sample size, library size and effect size. We also demonstrate the effectiveness of our novel framework using a published dataset of metastatic melanoma and find biological insights from the results.Availability and implementationThe R package 'RioNorm2' can be installed from Github athttps://github.com/yuanjing-ma/RioNorm2.Supplementary informationSupplementary data are available at Bioinformatics online.

Project description:Microarrays are widely used for examining differential gene expression, identifying single nucleotide polymorphisms, and detecting methylation loci. Multiple testing methods in microarray data analysis aim at controlling both Type I and Type II error rates; however, real microarray data do not always fit their distribution assumptions. Smyth's ubiquitous parametric method, for example, inadequately accommodates violations of normality assumptions, resulting in inflated Type I error rates. The Significance Analysis of Microarrays, another widely used microarray data analysis method, is based on a permutation test and is robust to non-normally distributed data; however, the Significance Analysis of Microarrays method fold change criteria are problematic, and can critically alter the conclusion of a study, as a result of compositional changes of the control data set in the analysis. We propose a novel approach, combining resampling with empirical Bayes methods: the Resampling-based empirical Bayes Methods. This approach not only reduces false discovery rates for non-normally distributed microarray data, but it is also impervious to fold change threshold since no control data set selection is needed. Through simulation studies, sensitivities, specificities, total rejections, and false discovery rates are compared across the Smyth's parametric method, the Significance Analysis of Microarrays, and the Resampling-based empirical Bayes Methods. Differences in false discovery rates controls between each approach are illustrated through a preterm delivery methylation study. The results show that the Resampling-based empirical Bayes Methods offer significantly higher specificity and lower false discovery rates compared to Smyth's parametric method when data are not normally distributed. The Resampling-based empirical Bayes Methods also offers higher statistical power than the Significance Analysis of Microarrays method when the proportion of significantly differentially expressed genes is large for both normally and non-normally distributed data. Finally, the Resampling-based empirical Bayes Methods are generalizable to next generation sequencing RNA-seq data analysis.

Dataset Information

An empirical Bayes approach to normalization and differential abundance testing for microbiome data.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets